Arcellx (ACLX) Receivables (2022 - 2023)

Arcellx (ACLX) recorded quarterly Receivables of $36.9 million in Q3 2023, down 37.23% quarter-over-quarter from $58.8 million in Q2 2023.

Arcellx (ACLX) Receivables (2022 - 2023) Analysis & Trends

Arcellx's Receivables history runs 2 years deep, the most recent figure standing at $36.9 million for Q3 2023.

In Q3 2023, Receivables changed N/A year-over-year to $36.9 million; the TTM figure through Sep 2023 stood at $36.9 million (changed N/A YoY), while the FY2022 annual figure was $2.0 million, changed N/A from the prior year.
Receivables was $36.9 million for Q3 2023 at Arcellx, down from $58.8 million in the prior quarter.
In the past five years, Receivables ranged from a high of $58.8 million in Q2 2023 to a low of $2.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Arcellx	6.48 Bn	6.48 Bn	-	-

Download Data